Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cell Therapy for Hematologic Malignancies
NCT03642626Phase 2Active, not recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2018
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel and idecabtagene vicleucel in acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and 1 more (7 arms), sponsored by Masonic Cancer Center. Primary endpoints: Overall Response Rate at Day 100 and Minimal Residual Disease-negative Complete Remission at Day 28. Started Dec 2018; status: active, not recruiting.
02
Drugs
tisagenlecleucelaxicabtagene ciloleucelbrexucabtagene autoleucellisocabtagene maraleucelidecabtagene vicleucel
03
Conditions
acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03642626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642626.